Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H E Wander

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
International Journal of Cancer|September 15, 1984
Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancerW Holtkamp, G A Nagel, H E Wander, et al.
Deutsche Medizinische Wochenschrift (1946)|April 22, 1983
[Determination of the carcinoembryonic antigen (CEA) for predicting the success of therapy in metastatic breast cancer]G Krieger, H E Wander, M Prangen, et al.
Onkologie|October 1, 1986
Phase-II studies of 1,2,4-triglycidylurazol (TGU) in solid tumors. Phase-II Study Group of the Association of Medical Oncology of the German Cancer SocietyW Queisser, H E Wander, K Possinger, et al.
International Journal of Cancer|February 15, 1983
Clinical significance of circulating immune complexes in patients with metastatic breast cancerG Krieger, A Kehl, H E Wander, et al.
Arzneimittel-Forschung|May 1, 1987
Medroxyprogesterone acetate and lipid metabolic changesA T Teichmann, H E Wander, P Cremer, et al.
Onkologie|April 1, 1987
[Megestrol acetate versus medroxyprogesterone acetate in the treatment of metastasizing breast cancers. Intermediate report of a multicenter phase III study]H E Wander, U R Kleeberg, E Gärtner, et al.
Onkologie|August 1, 1982
[Combined drug/hormone therapy in metastatic breast cancer with vincristine, adriamycin, cyclophosphamide and high dose medroxyprogesterone acetate--VAC-MAP. Preliminary results of a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force]H E Wander, G A Nagel, H C Blossey, et al.
Onkologie|February 1, 1991
Phase II study of vinorelbine by oral route (in a hard gelatine capsule) for metastatic breast cancer patients. A trial of the phase I/II study group of the Association for Medical Oncology of the German Cancer SocietyW Queisser, A Doss, H E Wander, et al.
Onkologie|April 1, 1985
[Changes in serum lipoproteins under hormonal therapy of breast carcinoma and other endocrine-dependent tumors]H E Wander, A T Teichmann, P Cremer, et al.
Onkologie|June 1, 1990
Phase II study of pirarubicin in metastatic breast cancerU R Kleeberg, L Reichel, H E Wander, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
International Journal of Cancer|September 15, 1984
Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancerW Holtkamp, G A Nagel, H E Wander, et al.
Deutsche Medizinische Wochenschrift (1946)|April 22, 1983
[Determination of the carcinoembryonic antigen (CEA) for predicting the success of therapy in metastatic breast cancer]G Krieger, H E Wander, M Prangen, et al.
Onkologie|October 1, 1986
Phase-II studies of 1,2,4-triglycidylurazol (TGU) in solid tumors. Phase-II Study Group of the Association of Medical Oncology of the German Cancer SocietyW Queisser, H E Wander, K Possinger, et al.
International Journal of Cancer|February 15, 1983
Clinical significance of circulating immune complexes in patients with metastatic breast cancerG Krieger, A Kehl, H E Wander, et al.
Arzneimittel-Forschung|May 1, 1987
Medroxyprogesterone acetate and lipid metabolic changesA T Teichmann, H E Wander, P Cremer, et al.
Onkologie|April 1, 1987
[Megestrol acetate versus medroxyprogesterone acetate in the treatment of metastasizing breast cancers. Intermediate report of a multicenter phase III study]H E Wander, U R Kleeberg, E Gärtner, et al.
Onkologie|August 1, 1982
[Combined drug/hormone therapy in metastatic breast cancer with vincristine, adriamycin, cyclophosphamide and high dose medroxyprogesterone acetate--VAC-MAP. Preliminary results of a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force]H E Wander, G A Nagel, H C Blossey, et al.
Onkologie|February 1, 1991
Phase II study of vinorelbine by oral route (in a hard gelatine capsule) for metastatic breast cancer patients. A trial of the phase I/II study group of the Association for Medical Oncology of the German Cancer SocietyW Queisser, A Doss, H E Wander, et al.
Onkologie|April 1, 1985
[Changes in serum lipoproteins under hormonal therapy of breast carcinoma and other endocrine-dependent tumors]H E Wander, A T Teichmann, P Cremer, et al.
Onkologie|June 1, 1990
Phase II study of pirarubicin in metastatic breast cancerU R Kleeberg, L Reichel, H E Wander, et al.
Pageof 4